nodes	percent_of_prediction	percent_of_DWPC	metapath
Zalcitabine—SLC22A6—Captopril—systemic scleroderma	0.127	0.251	CbGbCtD
Zalcitabine—SLC22A7—Methotrexate—systemic scleroderma	0.0946	0.187	CbGbCtD
Zalcitabine—CYP2C9—Leflunomide—systemic scleroderma	0.0745	0.147	CbGbCtD
Zalcitabine—CYP3A5—Mycophenolate mofetil—systemic scleroderma	0.0686	0.135	CbGbCtD
Zalcitabine—CYP2D6—Captopril—systemic scleroderma	0.0535	0.105	CbGbCtD
Zalcitabine—SLC22A6—Methotrexate—systemic scleroderma	0.0402	0.0793	CbGbCtD
Zalcitabine—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0268	0.0528	CbGbCtD
Zalcitabine—CYP3A4—Prednisone—systemic scleroderma	0.0214	0.0422	CbGbCtD
Zalcitabine—CYP2C9—cardial valve—systemic scleroderma	0.00712	0.48	CbGeAlD
Zalcitabine—DCK—Desoximetasone—Mometasone—systemic scleroderma	0.00154	0.328	CbGdCrCtD
Zalcitabine—DCK—Diflorasone—Mometasone—systemic scleroderma	0.0015	0.319	CbGdCrCtD
Zalcitabine—SLC29A2—tendon—systemic scleroderma	0.00121	0.0819	CbGeAlD
Zalcitabine—SLC29A1—connective tissue—systemic scleroderma	0.000876	0.0591	CbGeAlD
Zalcitabine—DCK—Desoximetasone—Prednisone—systemic scleroderma	0.000842	0.179	CbGdCrCtD
Zalcitabine—SLC22A7—digestive system—systemic scleroderma	0.00082	0.0553	CbGeAlD
Zalcitabine—DCK—Diflorasone—Prednisone—systemic scleroderma	0.000817	0.174	CbGdCrCtD
Zalcitabine—SLC29A1—digestive system—systemic scleroderma	0.000633	0.0427	CbGeAlD
Zalcitabine—DCK—digestive system—systemic scleroderma	0.000605	0.0408	CbGeAlD
Zalcitabine—SLC29A1—tendon—systemic scleroderma	0.000602	0.0406	CbGeAlD
Zalcitabine—DCK—tendon—systemic scleroderma	0.000575	0.0388	CbGeAlD
Zalcitabine—SLC29A1—lung—systemic scleroderma	0.000529	0.0356	CbGeAlD
Zalcitabine—DCK—lung—systemic scleroderma	0.000505	0.034	CbGeAlD
Zalcitabine—CYP3A5—digestive system—systemic scleroderma	0.000313	0.0211	CbGeAlD
Zalcitabine—CYP2C9—digestive system—systemic scleroderma	0.000308	0.0208	CbGeAlD
Zalcitabine—CYP3A5—lung—systemic scleroderma	0.000261	0.0176	CbGeAlD
Zalcitabine—Pancreatitis—Prednisone—systemic scleroderma	0.00026	0.000549	CcSEcCtD
Zalcitabine—Vomiting—Mometasone—systemic scleroderma	0.000259	0.000548	CcSEcCtD
Zalcitabine—Dry mouth—Lisinopril—systemic scleroderma	0.000259	0.000547	CcSEcCtD
Zalcitabine—Sweating increased—Prednisone—systemic scleroderma	0.000258	0.000545	CcSEcCtD
Zalcitabine—Feeling abnormal—Azathioprine—systemic scleroderma	0.000258	0.000544	CcSEcCtD
Zalcitabine—Rash—Mometasone—systemic scleroderma	0.000257	0.000543	CcSEcCtD
Zalcitabine—Asthenia—Captopril—systemic scleroderma	0.000257	0.000543	CcSEcCtD
Zalcitabine—Dermatitis—Mometasone—systemic scleroderma	0.000257	0.000543	CcSEcCtD
Zalcitabine—Decreased appetite—Leflunomide—systemic scleroderma	0.000257	0.000542	CcSEcCtD
Zalcitabine—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000257	0.000542	CcSEcCtD
Zalcitabine—Osteoarthritis—Methotrexate—systemic scleroderma	0.000256	0.000541	CcSEcCtD
Zalcitabine—Confusional state—Lisinopril—systemic scleroderma	0.000256	0.00054	CcSEcCtD
Zalcitabine—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000256	0.00054	CcSEcCtD
Zalcitabine—Headache—Mometasone—systemic scleroderma	0.000256	0.00054	CcSEcCtD
Zalcitabine—Tremor—Mycophenolate mofetil—systemic scleroderma	0.000255	0.000539	CcSEcCtD
Zalcitabine—Insomnia—Mycophenolic acid—systemic scleroderma	0.000255	0.000538	CcSEcCtD
Zalcitabine—Fatigue—Leflunomide—systemic scleroderma	0.000255	0.000538	CcSEcCtD
Zalcitabine—Oedema—Lisinopril—systemic scleroderma	0.000254	0.000536	CcSEcCtD
Zalcitabine—Pruritus—Captopril—systemic scleroderma	0.000254	0.000535	CcSEcCtD
Zalcitabine—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	0.000253	0.000534	CcSEcCtD
Zalcitabine—Pain—Leflunomide—systemic scleroderma	0.000253	0.000533	CcSEcCtD
Zalcitabine—Infection—Lisinopril—systemic scleroderma	0.000252	0.000532	CcSEcCtD
Zalcitabine—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.000252	0.000532	CcSEcCtD
Zalcitabine—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000251	0.000531	CcSEcCtD
Zalcitabine—Somnolence—Mycophenolic acid—systemic scleroderma	0.000251	0.000529	CcSEcCtD
Zalcitabine—Agitation—Mycophenolate mofetil—systemic scleroderma	0.00025	0.000529	CcSEcCtD
Zalcitabine—Shock—Lisinopril—systemic scleroderma	0.00025	0.000527	CcSEcCtD
Zalcitabine—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000249	0.000525	CcSEcCtD
Zalcitabine—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000248	0.000524	CcSEcCtD
Zalcitabine—Neutropenia—Prednisone—systemic scleroderma	0.000248	0.000523	CcSEcCtD
Zalcitabine—Tachycardia—Lisinopril—systemic scleroderma	0.000248	0.000523	CcSEcCtD
Zalcitabine—Abdominal pain—Azathioprine—systemic scleroderma	0.000247	0.000522	CcSEcCtD
Zalcitabine—Body temperature increased—Azathioprine—systemic scleroderma	0.000247	0.000522	CcSEcCtD
Zalcitabine—Skin disorder—Lisinopril—systemic scleroderma	0.000247	0.000521	CcSEcCtD
Zalcitabine—Malaise—Mycophenolate mofetil—systemic scleroderma	0.000246	0.000519	CcSEcCtD
Zalcitabine—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000245	0.000518	CcSEcCtD
Zalcitabine—Diarrhoea—Captopril—systemic scleroderma	0.000245	0.000518	CcSEcCtD
Zalcitabine—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000245	0.000517	CcSEcCtD
Zalcitabine—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.000245	0.000517	CcSEcCtD
Zalcitabine—Syncope—Mycophenolate mofetil—systemic scleroderma	0.000244	0.000516	CcSEcCtD
Zalcitabine—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000244	0.000515	CcSEcCtD
Zalcitabine—Feeling abnormal—Leflunomide—systemic scleroderma	0.000243	0.000514	CcSEcCtD
Zalcitabine—Fatigue—Mycophenolic acid—systemic scleroderma	0.000243	0.000513	CcSEcCtD
Zalcitabine—Mood swings—Methotrexate—systemic scleroderma	0.000243	0.000513	CcSEcCtD
Zalcitabine—Anorexia—Lisinopril—systemic scleroderma	0.000242	0.000511	CcSEcCtD
Zalcitabine—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000242	0.00051	CcSEcCtD
Zalcitabine—Ataxia—Methotrexate—systemic scleroderma	0.000241	0.000509	CcSEcCtD
Zalcitabine—Pain—Mycophenolic acid—systemic scleroderma	0.000241	0.000509	CcSEcCtD
Zalcitabine—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000241	0.000508	CcSEcCtD
Zalcitabine—Weight decreased—Prednisone—systemic scleroderma	0.00024	0.000506	CcSEcCtD
Zalcitabine—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000239	0.000506	CcSEcCtD
Zalcitabine—Hyperglycaemia—Prednisone—systemic scleroderma	0.000239	0.000505	CcSEcCtD
Zalcitabine—Cough—Mycophenolate mofetil—systemic scleroderma	0.000238	0.000502	CcSEcCtD
Zalcitabine—Dizziness—Captopril—systemic scleroderma	0.000237	0.0005	CcSEcCtD
Zalcitabine—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000236	0.000499	CcSEcCtD
Zalcitabine—Depression—Prednisone—systemic scleroderma	0.000236	0.000498	CcSEcCtD
Zalcitabine—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000235	0.000497	CcSEcCtD
Zalcitabine—CYP3A4—digestive system—systemic scleroderma	0.000235	0.0158	CbGeAlD
Zalcitabine—Urticaria—Leflunomide—systemic scleroderma	0.000235	0.000496	CcSEcCtD
Zalcitabine—Abdominal pain—Leflunomide—systemic scleroderma	0.000234	0.000493	CcSEcCtD
Zalcitabine—Body temperature increased—Leflunomide—systemic scleroderma	0.000234	0.000493	CcSEcCtD
Zalcitabine—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000232	0.00049	CcSEcCtD
Zalcitabine—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000232	0.00049	CcSEcCtD
Zalcitabine—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000232	0.00049	CcSEcCtD
Zalcitabine—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000232	0.000489	CcSEcCtD
Zalcitabine—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000231	0.000488	CcSEcCtD
Zalcitabine—CYP2D6—digestive system—systemic scleroderma	0.000231	0.0156	CbGeAlD
Zalcitabine—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000231	0.000488	CcSEcCtD
Zalcitabine—Hypersensitivity—Azathioprine—systemic scleroderma	0.00023	0.000487	CcSEcCtD
Zalcitabine—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.00023	0.000487	CcSEcCtD
Zalcitabine—Insomnia—Lisinopril—systemic scleroderma	0.00023	0.000485	CcSEcCtD
Zalcitabine—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000229	0.000484	CcSEcCtD
Zalcitabine—Vomiting—Captopril—systemic scleroderma	0.000228	0.000481	CcSEcCtD
Zalcitabine—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000227	0.000479	CcSEcCtD
Zalcitabine—Dyspnoea—Lisinopril—systemic scleroderma	0.000226	0.000478	CcSEcCtD
Zalcitabine—Rash—Captopril—systemic scleroderma	0.000226	0.000477	CcSEcCtD
Zalcitabine—Dermatitis—Captopril—systemic scleroderma	0.000226	0.000477	CcSEcCtD
Zalcitabine—Somnolence—Lisinopril—systemic scleroderma	0.000226	0.000476	CcSEcCtD
Zalcitabine—Headache—Captopril—systemic scleroderma	0.000225	0.000474	CcSEcCtD
Zalcitabine—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000224	0.000474	CcSEcCtD
Zalcitabine—Dyspepsia—Lisinopril—systemic scleroderma	0.000223	0.000472	CcSEcCtD
Zalcitabine—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000223	0.00047	CcSEcCtD
Zalcitabine—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000223	0.00047	CcSEcCtD
Zalcitabine—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000222	0.00047	CcSEcCtD
Zalcitabine—Infection—Mycophenolate mofetil—systemic scleroderma	0.000221	0.000467	CcSEcCtD
Zalcitabine—Decreased appetite—Lisinopril—systemic scleroderma	0.000221	0.000466	CcSEcCtD
Zalcitabine—Eosinophilia—Methotrexate—systemic scleroderma	0.000219	0.000463	CcSEcCtD
Zalcitabine—Fatigue—Lisinopril—systemic scleroderma	0.000219	0.000462	CcSEcCtD
Zalcitabine—Shock—Mycophenolate mofetil—systemic scleroderma	0.000219	0.000462	CcSEcCtD
Zalcitabine—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000218	0.00046	CcSEcCtD
Zalcitabine—Hypersensitivity—Leflunomide—systemic scleroderma	0.000218	0.00046	CcSEcCtD
Zalcitabine—Pancreatitis—Methotrexate—systemic scleroderma	0.000217	0.000459	CcSEcCtD
Zalcitabine—Pain—Lisinopril—systemic scleroderma	0.000217	0.000458	CcSEcCtD
Zalcitabine—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000217	0.000458	CcSEcCtD
Zalcitabine—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000216	0.000456	CcSEcCtD
Zalcitabine—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000215	0.000454	CcSEcCtD
Zalcitabine—Diarrhoea—Azathioprine—systemic scleroderma	0.000214	0.000452	CcSEcCtD
Zalcitabine—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000212	0.000448	CcSEcCtD
Zalcitabine—Asthenia—Leflunomide—systemic scleroderma	0.000212	0.000448	CcSEcCtD
Zalcitabine—Hallucination—Prednisone—systemic scleroderma	0.000211	0.000446	CcSEcCtD
Zalcitabine—Feeling abnormal—Lisinopril—systemic scleroderma	0.000209	0.000442	CcSEcCtD
Zalcitabine—Pruritus—Leflunomide—systemic scleroderma	0.000209	0.000441	CcSEcCtD
Zalcitabine—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000208	0.000438	CcSEcCtD
Zalcitabine—Dysuria—Methotrexate—systemic scleroderma	0.000207	0.000437	CcSEcCtD
Zalcitabine—Neutropenia—Methotrexate—systemic scleroderma	0.000207	0.000437	CcSEcCtD
Zalcitabine—Dizziness—Azathioprine—systemic scleroderma	0.000207	0.000437	CcSEcCtD
Zalcitabine—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000203	0.000428	CcSEcCtD
Zalcitabine—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.000202	0.000427	CcSEcCtD
Zalcitabine—Asthenia—Mycophenolic acid—systemic scleroderma	0.000202	0.000427	CcSEcCtD
Zalcitabine—Diarrhoea—Leflunomide—systemic scleroderma	0.000202	0.000427	CcSEcCtD
Zalcitabine—Urticaria—Lisinopril—systemic scleroderma	0.000202	0.000426	CcSEcCtD
Zalcitabine—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000201	0.000425	CcSEcCtD
Zalcitabine—Abdominal pain—Lisinopril—systemic scleroderma	0.000201	0.000424	CcSEcCtD
Zalcitabine—Body temperature increased—Lisinopril—systemic scleroderma	0.000201	0.000424	CcSEcCtD
Zalcitabine—Pruritus—Mycophenolic acid—systemic scleroderma	0.000199	0.000421	CcSEcCtD
Zalcitabine—Vomiting—Azathioprine—systemic scleroderma	0.000199	0.00042	CcSEcCtD
Zalcitabine—Eye disorder—Prednisone—systemic scleroderma	0.000198	0.000419	CcSEcCtD
Zalcitabine—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000198	0.000419	CcSEcCtD
Zalcitabine—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000198	0.000417	CcSEcCtD
Zalcitabine—Rash—Azathioprine—systemic scleroderma	0.000197	0.000416	CcSEcCtD
Zalcitabine—Dermatitis—Azathioprine—systemic scleroderma	0.000197	0.000416	CcSEcCtD
Zalcitabine—Depression—Methotrexate—systemic scleroderma	0.000197	0.000416	CcSEcCtD
Zalcitabine—Flushing—Prednisone—systemic scleroderma	0.000197	0.000416	CcSEcCtD
Zalcitabine—Headache—Azathioprine—systemic scleroderma	0.000196	0.000414	CcSEcCtD
Zalcitabine—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000196	0.000413	CcSEcCtD
Zalcitabine—Dizziness—Leflunomide—systemic scleroderma	0.000195	0.000412	CcSEcCtD
Zalcitabine—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000193	0.000408	CcSEcCtD
Zalcitabine—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000193	0.000407	CcSEcCtD
Zalcitabine—Pain—Mycophenolate mofetil—systemic scleroderma	0.00019	0.000402	CcSEcCtD
Zalcitabine—Arrhythmia—Prednisone—systemic scleroderma	0.00019	0.0004	CcSEcCtD
Zalcitabine—Vomiting—Leflunomide—systemic scleroderma	0.000188	0.000397	CcSEcCtD
Zalcitabine—Alopecia—Prednisone—systemic scleroderma	0.000187	0.000396	CcSEcCtD
Zalcitabine—Hypersensitivity—Lisinopril—systemic scleroderma	0.000187	0.000395	CcSEcCtD
Zalcitabine—Dizziness—Mycophenolic acid—systemic scleroderma	0.000186	0.000393	CcSEcCtD
Zalcitabine—Epistaxis—Methotrexate—systemic scleroderma	0.000186	0.000393	CcSEcCtD
Zalcitabine—Rash—Leflunomide—systemic scleroderma	0.000186	0.000393	CcSEcCtD
Zalcitabine—Dermatitis—Leflunomide—systemic scleroderma	0.000186	0.000393	CcSEcCtD
Zalcitabine—Headache—Leflunomide—systemic scleroderma	0.000185	0.000391	CcSEcCtD
Zalcitabine—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000183	0.000387	CcSEcCtD
Zalcitabine—Asthenia—Lisinopril—systemic scleroderma	0.000182	0.000385	CcSEcCtD
Zalcitabine—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000182	0.000384	CcSEcCtD
Zalcitabine—Pruritus—Lisinopril—systemic scleroderma	0.00018	0.000379	CcSEcCtD
Zalcitabine—Vomiting—Mycophenolic acid—systemic scleroderma	0.000179	0.000378	CcSEcCtD
Zalcitabine—Rash—Mycophenolic acid—systemic scleroderma	0.000178	0.000375	CcSEcCtD
Zalcitabine—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000178	0.000375	CcSEcCtD
Zalcitabine—Hepatitis—Methotrexate—systemic scleroderma	0.000177	0.000374	CcSEcCtD
Zalcitabine—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000177	0.000373	CcSEcCtD
Zalcitabine—Headache—Mycophenolic acid—systemic scleroderma	0.000177	0.000373	CcSEcCtD
Zalcitabine—Pharyngitis—Methotrexate—systemic scleroderma	0.000176	0.000372	CcSEcCtD
Zalcitabine—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000176	0.000371	CcSEcCtD
Zalcitabine—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000176	0.000371	CcSEcCtD
Zalcitabine—Vision blurred—Prednisone—systemic scleroderma	0.000174	0.000368	CcSEcCtD
Zalcitabine—Diarrhoea—Lisinopril—systemic scleroderma	0.000174	0.000367	CcSEcCtD
Zalcitabine—Ill-defined disorder—Prednisone—systemic scleroderma	0.000171	0.000362	CcSEcCtD
Zalcitabine—Visual impairment—Methotrexate—systemic scleroderma	0.000171	0.000361	CcSEcCtD
Zalcitabine—Anaemia—Prednisone—systemic scleroderma	0.000171	0.00036	CcSEcCtD
Zalcitabine—Agitation—Prednisone—systemic scleroderma	0.00017	0.000358	CcSEcCtD
Zalcitabine—Dizziness—Lisinopril—systemic scleroderma	0.000168	0.000354	CcSEcCtD
Zalcitabine—Malaise—Prednisone—systemic scleroderma	0.000167	0.000352	CcSEcCtD
Zalcitabine—Vertigo—Prednisone—systemic scleroderma	0.000166	0.00035	CcSEcCtD
Zalcitabine—Eye disorder—Methotrexate—systemic scleroderma	0.000166	0.00035	CcSEcCtD
Zalcitabine—Syncope—Prednisone—systemic scleroderma	0.000166	0.00035	CcSEcCtD
Zalcitabine—Tinnitus—Methotrexate—systemic scleroderma	0.000165	0.000349	CcSEcCtD
Zalcitabine—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000164	0.000346	CcSEcCtD
Zalcitabine—Loss of consciousness—Prednisone—systemic scleroderma	0.000162	0.000343	CcSEcCtD
Zalcitabine—Vomiting—Lisinopril—systemic scleroderma	0.000161	0.000341	CcSEcCtD
Zalcitabine—Rash—Lisinopril—systemic scleroderma	0.00016	0.000338	CcSEcCtD
Zalcitabine—Convulsion—Prednisone—systemic scleroderma	0.00016	0.000338	CcSEcCtD
Zalcitabine—Dermatitis—Lisinopril—systemic scleroderma	0.00016	0.000338	CcSEcCtD
Zalcitabine—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.00016	0.000337	CcSEcCtD
Zalcitabine—Hypertension—Prednisone—systemic scleroderma	0.000159	0.000337	CcSEcCtD
Zalcitabine—Chills—Methotrexate—systemic scleroderma	0.000159	0.000336	CcSEcCtD
Zalcitabine—Headache—Lisinopril—systemic scleroderma	0.000159	0.000336	CcSEcCtD
Zalcitabine—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000157	0.000332	CcSEcCtD
Zalcitabine—Arthralgia—Prednisone—systemic scleroderma	0.000157	0.000332	CcSEcCtD
Zalcitabine—Myalgia—Prednisone—systemic scleroderma	0.000157	0.000332	CcSEcCtD
Zalcitabine—Anxiety—Prednisone—systemic scleroderma	0.000157	0.000331	CcSEcCtD
Zalcitabine—Alopecia—Methotrexate—systemic scleroderma	0.000157	0.000331	CcSEcCtD
Zalcitabine—Discomfort—Prednisone—systemic scleroderma	0.000155	0.000328	CcSEcCtD
Zalcitabine—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000152	0.000321	CcSEcCtD
Zalcitabine—Dysgeusia—Methotrexate—systemic scleroderma	0.000151	0.000319	CcSEcCtD
Zalcitabine—Oedema—Prednisone—systemic scleroderma	0.000151	0.000318	CcSEcCtD
Zalcitabine—Infection—Prednisone—systemic scleroderma	0.00015	0.000316	CcSEcCtD
Zalcitabine—Back pain—Methotrexate—systemic scleroderma	0.000149	0.000315	CcSEcCtD
Zalcitabine—Shock—Prednisone—systemic scleroderma	0.000148	0.000313	CcSEcCtD
Zalcitabine—Tachycardia—Prednisone—systemic scleroderma	0.000147	0.000311	CcSEcCtD
Zalcitabine—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000147	0.000311	CcSEcCtD
Zalcitabine—Skin disorder—Prednisone—systemic scleroderma	0.000146	0.000309	CcSEcCtD
Zalcitabine—Hyperhidrosis—Prednisone—systemic scleroderma	0.000146	0.000308	CcSEcCtD
Zalcitabine—Vision blurred—Methotrexate—systemic scleroderma	0.000145	0.000307	CcSEcCtD
Zalcitabine—Anorexia—Prednisone—systemic scleroderma	0.000144	0.000303	CcSEcCtD
Zalcitabine—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000143	0.000302	CcSEcCtD
Zalcitabine—Anaemia—Methotrexate—systemic scleroderma	0.000143	0.000301	CcSEcCtD
Zalcitabine—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000141	0.000299	CcSEcCtD
Zalcitabine—Rash—Mycophenolate mofetil—systemic scleroderma	0.00014	0.000296	CcSEcCtD
Zalcitabine—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.00014	0.000296	CcSEcCtD
Zalcitabine—Headache—Mycophenolate mofetil—systemic scleroderma	0.000139	0.000294	CcSEcCtD
Zalcitabine—Malaise—Methotrexate—systemic scleroderma	0.000139	0.000294	CcSEcCtD
Zalcitabine—Vertigo—Methotrexate—systemic scleroderma	0.000139	0.000293	CcSEcCtD
Zalcitabine—Leukopenia—Methotrexate—systemic scleroderma	0.000138	0.000292	CcSEcCtD
Zalcitabine—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000137	0.00029	CcSEcCtD
Zalcitabine—Insomnia—Prednisone—systemic scleroderma	0.000136	0.000288	CcSEcCtD
Zalcitabine—Cough—Methotrexate—systemic scleroderma	0.000135	0.000284	CcSEcCtD
Zalcitabine—Convulsion—Methotrexate—systemic scleroderma	0.000134	0.000282	CcSEcCtD
Zalcitabine—Dyspepsia—Prednisone—systemic scleroderma	0.000133	0.00028	CcSEcCtD
Zalcitabine—Arthralgia—Methotrexate—systemic scleroderma	0.000131	0.000278	CcSEcCtD
Zalcitabine—Myalgia—Methotrexate—systemic scleroderma	0.000131	0.000278	CcSEcCtD
Zalcitabine—Decreased appetite—Prednisone—systemic scleroderma	0.000131	0.000277	CcSEcCtD
Zalcitabine—Fatigue—Prednisone—systemic scleroderma	0.00013	0.000274	CcSEcCtD
Zalcitabine—Discomfort—Methotrexate—systemic scleroderma	0.00013	0.000274	CcSEcCtD
Zalcitabine—Confusional state—Methotrexate—systemic scleroderma	0.000127	0.000268	CcSEcCtD
Zalcitabine—Infection—Methotrexate—systemic scleroderma	0.000125	0.000264	CcSEcCtD
Zalcitabine—Feeling abnormal—Prednisone—systemic scleroderma	0.000124	0.000262	CcSEcCtD
Zalcitabine—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000123	0.00026	CcSEcCtD
Zalcitabine—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000123	0.00026	CcSEcCtD
Zalcitabine—Skin disorder—Methotrexate—systemic scleroderma	0.000122	0.000258	CcSEcCtD
Zalcitabine—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000122	0.000257	CcSEcCtD
Zalcitabine—Anorexia—Methotrexate—systemic scleroderma	0.00012	0.000254	CcSEcCtD
Zalcitabine—Urticaria—Prednisone—systemic scleroderma	0.00012	0.000253	CcSEcCtD
Zalcitabine—Abdominal pain—Prednisone—systemic scleroderma	0.000119	0.000252	CcSEcCtD
Zalcitabine—Body temperature increased—Prednisone—systemic scleroderma	0.000119	0.000252	CcSEcCtD
Zalcitabine—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000115	0.000242	CcSEcCtD
Zalcitabine—Insomnia—Methotrexate—systemic scleroderma	0.000114	0.000241	CcSEcCtD
Zalcitabine—Dyspnoea—Methotrexate—systemic scleroderma	0.000112	0.000237	CcSEcCtD
Zalcitabine—Somnolence—Methotrexate—systemic scleroderma	0.000112	0.000237	CcSEcCtD
Zalcitabine—Hypersensitivity—Prednisone—systemic scleroderma	0.000111	0.000235	CcSEcCtD
Zalcitabine—Dyspepsia—Methotrexate—systemic scleroderma	0.000111	0.000234	CcSEcCtD
Zalcitabine—Decreased appetite—Methotrexate—systemic scleroderma	0.00011	0.000231	CcSEcCtD
Zalcitabine—Fatigue—Methotrexate—systemic scleroderma	0.000109	0.000229	CcSEcCtD
Zalcitabine—Asthenia—Prednisone—systemic scleroderma	0.000108	0.000228	CcSEcCtD
Zalcitabine—Pain—Methotrexate—systemic scleroderma	0.000108	0.000227	CcSEcCtD
Zalcitabine—Pruritus—Prednisone—systemic scleroderma	0.000107	0.000225	CcSEcCtD
Zalcitabine—Feeling abnormal—Methotrexate—systemic scleroderma	0.000104	0.000219	CcSEcCtD
Zalcitabine—Diarrhoea—Prednisone—systemic scleroderma	0.000103	0.000218	CcSEcCtD
Zalcitabine—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000103	0.000218	CcSEcCtD
Zalcitabine—Urticaria—Methotrexate—systemic scleroderma	0.0001	0.000211	CcSEcCtD
Zalcitabine—Dizziness—Prednisone—systemic scleroderma	9.97e-05	0.00021	CcSEcCtD
Zalcitabine—Body temperature increased—Methotrexate—systemic scleroderma	9.96e-05	0.00021	CcSEcCtD
Zalcitabine—Abdominal pain—Methotrexate—systemic scleroderma	9.96e-05	0.00021	CcSEcCtD
Zalcitabine—Vomiting—Prednisone—systemic scleroderma	9.58e-05	0.000202	CcSEcCtD
Zalcitabine—Rash—Prednisone—systemic scleroderma	9.5e-05	0.000201	CcSEcCtD
Zalcitabine—Dermatitis—Prednisone—systemic scleroderma	9.5e-05	0.000201	CcSEcCtD
Zalcitabine—Headache—Prednisone—systemic scleroderma	9.44e-05	0.000199	CcSEcCtD
Zalcitabine—Hypersensitivity—Methotrexate—systemic scleroderma	9.28e-05	0.000196	CcSEcCtD
Zalcitabine—Asthenia—Methotrexate—systemic scleroderma	9.04e-05	0.000191	CcSEcCtD
Zalcitabine—Pruritus—Methotrexate—systemic scleroderma	8.91e-05	0.000188	CcSEcCtD
Zalcitabine—Diarrhoea—Methotrexate—systemic scleroderma	8.62e-05	0.000182	CcSEcCtD
Zalcitabine—Dizziness—Methotrexate—systemic scleroderma	8.33e-05	0.000176	CcSEcCtD
Zalcitabine—Vomiting—Methotrexate—systemic scleroderma	8.01e-05	0.000169	CcSEcCtD
Zalcitabine—Rash—Methotrexate—systemic scleroderma	7.94e-05	0.000168	CcSEcCtD
Zalcitabine—Dermatitis—Methotrexate—systemic scleroderma	7.94e-05	0.000168	CcSEcCtD
Zalcitabine—Headache—Methotrexate—systemic scleroderma	7.89e-05	0.000167	CcSEcCtD
